Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? by Seeliger, B. et al.
                          Seeliger, B., Sznajd, J., Robson, J. C., Judge, A., Craven, A., Grayson, P. C.,
... Luqmani, R. A. (2017). Are the 1990 American College of Rheumatology
vasculitis classification criteria still valid? Rheumatology, 56(7), 1154-1161.
https://doi.org/10.1093/rheumatology/kex075
Peer reviewed version
License (if available):
Other
Link to published version (if available):
10.1093/rheumatology/kex075
Link to publication record in Explore Bristol Research
PDF-document
This is the accepted author manuscript (AAM). The final published version (version of record) is available online
via OUP at https://doi.org/10.1093/rheumatology/kex075 . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Reappraisal of the 1990 American College of Rheumatology classification criteria for 
systemic vasculitis – Analysis of data from the Diagnostic & Classification Criteria in 
Vasculitis Study (DCVAS) 
Benjamin Seeliger1,2*, Jan Sznajd2,3*, Joanna C Robson2, Andrew Judge2,4, Anthea Craven2, Peter C 
Grayson5, Ravi S Suppiah6, Richard A Watts7, Peter A Merkel8, Raashid A Luqmani2 for the DCVAS 
Investigators 
1 Hannover Medical School, Department of Respiratory Medicine, Hanover, Germany; 2 Nuffield 
Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, 
Oxford, United Kingdom; 3 Department of Internal Medicine, Jagiellonian University Medical School, 
Cracow, Poland; 4 MRC Lifecourse Epidemiology Unit, University of Southampton, United Kingdom; 5 
National Institutes of Health/NIAMS, Bethesda, MD, USA; 6 Department of Rheumatology, Auckland 
District Health Board, Auckland, New Zealand; 7 Norwich Medical School, University of East Anglia, 
Norwich; 8 University of Pennsylvania, Philadelphia, USA 
*B Seeliger and J Sznajd contributed equally to this study. 
Corresponding Author: Raashid Ahmed Luqmani, University of Oxford, Nuffield Department of 
Orthopaedics, Rheumatology and Musculoskeletal Sciences, Windmill Road, OXFORD, OX3 7HE, 
United Kingdom, raashid.luqmani@ndorms.ox.ac.uk, +44 (0)1865 227374. 
The Diagnosis and Classification in Vasculitis Study (DCVAS) is a major international research initiative 
supported in part by the Vasculitis Foundation. The development of a revised single classification 
system for the vasculitides is being supported by the American College of Rheumatology and the 
European League Against Rheumatism. 
Running title: Reappraisal of the 1990 ACR Criteria for PSV 
Keywords: Vasculitis; Churg-Strauss-Syndrome; Giant cell arteritis; Polyarteritis nodosa; Anti-
neutrophil cytoplasm antibody; Wegener’s granulomatosis; Takayasu’s disease; Microscopic 
Polyangiits 
ABSTRACT 
Objectives. Advances in diagnostic techniques have led to better distinction between types of 
vasculitis, potentially affecting the utility of the 1990 American College of Rheumatology (ACR) 
classification criteria for vasculitis. This study tested the performance of these criteria in a 
contemporary vasculitis cohort. 
Methods. The Diagnosis and Classification in Vasculitis Study provided detailed clinical, serological, 
pathological, and radiological data from patients with primary systemic vasculitis (PSV) and clinical 
context-specific comparator conditions. Fulfilment of six ACR criteria sets and their diagnostic 
performance was evaluated in patients with a given type of vasculitis and its comparator conditions. 
Results. Data from 1095 patients with PSV and 415 with comparator conditions were available. For 
classification, sensitivities and specificities for ACR classification criteria were 81.1% and 94.9% for 
giant cell arteritis; 73.6% and 98.3% for Takayasu’s arteritis; 65.6% and 88.7% for granulomatosis with 
polyangiitis; 57.0% and 99.8% for eosinophilic granulomatosis with polyangiitis; 40.6% and 87.8% for 
polyarteritis nodosa; 28.9% and 88.5% for microscopic polyangiitis; and 72.7% and 96.3% for IgA-
vasculitis. Overall sensitivity was 67.1%. 16.9% of cases identified by their respective criteria also met 
criteria for other vasculitides. Diagnostic specificity ranged from 64.2 to 98.9%; overall, 113/415 
comparators (27.2%) fulfilled at least one of the ACR classification criteria sets. 
Conclusions. Since publication of the ACR criteria for vasculitis, the sensitivity for each type of 
vasculitis, except giant cell arteritis, has diminished, although the specificities have remained high, 
highlighting the need for updated classification criteria.  
INTRODUCTION  
In 1990, the American College of Rheumatology (ACR) published criteria for the classification of seven 
types of systemic vasculitis: giant cell arteritis (GCA), Takayasu’s arteritis (TAK), eosinophilic 
granulomatosis with polyangiitis (Churg-Strauss, EGPA), granulomatosis with polyangiitis (Wegener’s, 
GPA), polyarteritis nodosa (PAN), IgA vasculitis (Henoch-Schönlein, IgAV) and hypersensitivity 
vasculitis [1]. 
Although the 1990 ACR Classification Criteria have been widely applied in clinical studies and 
facilitated research in vasculitis, they also have important limitations [2]. Firstly, microscopic 
polyangiitis (MPA) was not one of the named conditions because it was not a widely-recognised 
condition in the 1980s. Secondly, the criteria were developed before the widespread use of testing for 
anti-neutrophil cytoplasm antibodies (ANCA) which has since become a fundamental aspect in the 
diagnosis and classification of ANCA-associated vasculitis (AAV) [3]. Thirdly, introduction and 
widespread use of new diagnostic techniques (e.g. computerised tomography and magnetic 
resonance imaging) have contributed to a better distinction between different types of vasculitis [4, 
5]. Although their suboptimal performance in classification of vasculitides has been previously 
documented in several studies [6–9], they are still used in clinical research. Furthermore, many 
clinicians apply the ACR criteria in clinical practice for diagnosis, although these criteria were not 
designed for this purpose and are inadequate as diagnostic tools [10]. We aimed to test whether the 
1990 ACR classification criteria would perform similarly in a large international and more 
heterogeneous cohort of vasculitis patients recruited to the “Diagnosis and Classification of Vasculitis 
Study” (DCVAS), a major international research initiative to develop a revised single classification 
system and a validated set of diagnostic criteria for the vasculitides. 
This analysis tested the performance of six of the 1990 ACR classification criteria for vasculitis for use 
in both classification (original intent) and diagnosis of patients with vasculitis and comparator 
conditions enrolled in the DCVAS.  
METHODS 
Patients and inclusion criteria 
The data source was the DCVAS project, a prospective multi-centre study to develop diagnostic and 
classification criteria in vasculitis [10], and included all patients recruited between September 2010 
and June 2014. The dataset has detailed clinical, serological, pathological, and radiological data from 
patients with primary systemic vasculitis (PSV) and patients with clinical context-specific comparator 
conditions. The detailed methodology of the DCVAS study has been described elsewhere [11]. The 
physicians submitting cases were asked to confirm their opinion on the diagnosis and their level of 
diagnostic certainty (very certain, ≥75%; moderately certain, 50-74%; uncertain, 25-49%; very 
uncertain, <25%) for each patient. Included in this analysis was data from patients with a baseline 
diagnosis of any PSV with a recorded confidence in diagnosis of ≥75% by the submitting clinician, as 
well as patients with conditions considered to be comparators for GCA, TAK, AAV, PAN and IgAV 
(definitions shown in supplementary Table S1, available at Rheumatology online). Patients who had a 
change of diagnosis at the six months follow-up, and patients with GPA or MPA without either a 
positive ANCA test or a biopsy were excluded from the analysis, because certainty of the initial 
diagnosis was deemed insufficient. 
Analysis 
The presence of each individual ACR criterion was evaluated in each case of PSV. The 1990 ACR 
classification criteria were considered fulfilled if the specified number of features for each criteria set 
was met (e.g. 3 out of 5 for GCA). The definitions for each criterion are shown in supplementary Table 
S2, available at Rheumatology online. Criteria involving imaging data were considered present based 
on either the originally described methods (e.g. conventional angiography) or by using current 
comparable methods (magnetic resonance angiography or computerized tomography angiography). 
Missing information was considered absent. 
Each of the six sets of the 1990 ACR criteria was tested against all patients with PSV in the DCVAS 
cohort (including patients with other types of vasculitis not covered by the ACR criteria) to assess the 
sensitivity and specificity of the criteria for classification of GCA, TAK, GPA, EGPA, PAN, and IgAV. The 
ACR criteria for hypersensitivity vasculitis were not assessed due to low patient numbers (n=9); these 
patients were included as patients with other forms of PSV. Diagnostic specificity was evaluated by 
applying the respective criteria sets to patients with each given type of vasculitis and their 
comparators. (e.g. all patients with GCA plus GCA-comparators). Physician-submitted diagnosis was 
considered to be the gold standard. Because there was no distinction between PAN and MPA in the 
original ACR criteria, the ACR PAN criteria were used for both PAN and MPA in the DCVAS cohort, 
although we fully appreciate that this is a somewhat academic exercise.  
RESULTS 
Patients and diagnostic workup  
Data from 2116 patients (1570 with PSV; 564 with comparator conditions) from 85 centres worldwide 
were available (Figure 1). Six-hundred-six patients (475 with PSV; 131 with comparator conditions) 
were excluded. In total, 1095 patients with a physician-submitted diagnosis of PSV were included in 
the analysis; 944 of these patients had one of the diagnoses for which ACR classification criteria are 
available, 151 had other types of PSV (Table 1). These 1095 patients were used to assess the criteria 
performance for classification. Four hundred and fifteen patients who did not have vasculitis were 
included in the analysis as comparators to assess diagnostic performance of the criteria; 38.3% of the 
comparator cases were included in more than one comparator group. An overview of clinical 
conditions in the comparator patients is shown in supplementary Table S3, available at Rheumatology 
online. 
The number of imaging procedures, biopsies, and tests for ANCA, with the average number of 
investigations performed by contributing centres in the main vasculitis categories, are presented in 
Table 2. In 60 (5.5%) patients with PSV and 22 (5.3%) comparators, neither an imaging study, nor a 
biopsy had been performed; in 21 (1.1%) and 5 (1.2%) data was missing in these categories, 
respectively. 
Performance of the criteria for classification 
The performance of the individual 1990 ACR classification criteria for sensitivity and specificity within 
the DCVAS cohort is shown in Table 1. For classification, the sensitivity of the 1990 ACR criteria ranged 
from 81.1% for GCA to 28.9% for MPA and the specificity ranged from 99.8% for EGPA to 88.5% in 
MPA (using the PAN criteria). 
The sensitivity of the criteria for GPA and EGPA improved when a positive ANCA was considered as a 
surrogate for a positive biopsy: GPA: 90.5 [CI: 86.5 – 93.7]; EGPA: 68.4 [CI: 56.9 – 78.4]. Specificity 
remained high in EGPA (98.3 [CI: 97.3 – 99.0]), but was reduced in GPA (68.4 [CI: 56.9 – 78.4]). Applying 
solely positive PR3-ANCA as biopsy surrogate for GPA yielded a sensitivity of 89.1% [CI: 84.8 – 92.5] 
and a specificity of 85.1% [CI: 82.5 – 87.5]. 
There was substantial heterogeneity in sensitivity and specificity across centres for most of the 
diagnoses, however the number of cases with certain PSV was quite low in some centres 
(Supplementary Table S4, available at Rheumatology online). 
Overall performance of the criteria 
Overall, 633 of 944 patients with one of the forms of vasculitis covered by the ACR criteria were 
captured by the ACR classification criteria (sensitivity 67.1 %). 267 of all 1095 patients with PSV (24.4%) 
fulfilled criteria for at least one condition other than their physician-submitted diagnosis, including 
107 of 633 patients (16.9%) who were correctly captured by ACR criteria. Overall accuracy and overlap 
of the application of the 1990 ACR criteria is illustrated by Figure 2. 
Diagnostic performance of the criteria 
When applied as diagnostic criteria, i.e. to patients with a given type of vasculitis and its disease 
context comparators, the specificity of the ACR criteria ranged from 64.2% in GCA to 98.9% in EGPA 
(Table 1); overall 113 of 415 (27.2%) patients with vasculitis comparator conditions fulfilled one of the 
ACR classification criteria sets. 
Differences between patients captured and patients not captured by the criteria 
Table 3 and supplementary Table S5, available at Rheumatology online, compare the demographic 
characteristics, disease manifestations, and fulfilment of individual ACR criteria in patients with 
physician-submitted diagnosis concordant with 1990 ACR criteria or not (“correctly” vs “not correctly” 
classified). Compared to patients “correctly” classified per ACR criteria (true positives), patients who 
were “not correctly” classified (false negatives) had fewer of each ACR criteria (online supplementary 
Table S5). However, in terms of non-criteria characteristics (Table 2.), the percentage of positive ANCA 
tests in both groups of patients with AAV were comparably high (87.4% vs 87.8%; p=0.984). Similarly, 
the groups did not differ in terms of positive biopsy results (70.5% vs 71.2%; p=0.881), when less 
stringent than ACR biopsy definitions were applied (“biopsy consistent with vasculitis but not definite” 
or “definite vasculitis”). In contrast, only 5.5% of patients with GPA or EGPA not captured by the 
criteria met the corresponding original ACR biopsy definitions. Patients with large vessel vasculitis 
(GCA or TAK) who were “not correctly” classified were more likely to have abnormal findings on 
angiography and positron emission tomography scans.  
DISCUSSION 
This analysis demonstrates that the sensitivity of the 1990 ACR classification criteria has declined 
substantially over the last two decades. Overall, one-third of patients who had a physician-submitted 
diagnosis consistent with one of the types of vasculitis covered by the ACR criteria were not correctly 
classified by using the criteria. This was most striking with GPA and EGPA and may reflect improved 
recognition of a wider spectrum of disease and greater reliance on novel diagnostic tests, especially 
due to routine testing for ANCA [12]. ANCA testing is especially helpful in the diagnosis of GPA and 
MPA, adds to the specificity for EGPA, and their presence helps rule out PAN [5]. 
Individual ACR criteria items were less frequently fulfilled in those cases with PSV who were not 
classified in agreement with the physician’s diagnosis than in cases who were correctly classified. 
While this is an expected finding, it likely reflects the greater reliance on diagnostic tools not covered 
by the ACR criteria. Furthermore, results of ANCA tests, modern imaging modalities, and biopsies with 
less stringent definitions were positive in the majority of patients not captured by the ACR criteria. 
Thus, the stringency of the definitions for biopsy positivity and lack of inclusion of modern imaging 
tools and ANCA in the criteria may have had a large impact on the sensitivity of the ACR criteria. 
Indeed, sensitivity of the criteria for GPA improved when proteinase-3 ANCA was used as a surrogate 
for ACR biopsy criterion with almost no loss of specificity. Newer diagnostic tools may have enabled 
an expansion of the clinical phenotype described within disease subtypes and broadened the 
appreciation of overlap between diseases, including the spectrum of large vessel disease, and the 
overlap between classification of patients with small vessel vasculitis and PAN [10, 13, 14]. This 
expansion of the spectrum of disease can reduce sensitivity of classification criteria as shown in this 
study. 
The sensitivity for PAN of 40.6% was particularly low compared to the originally reported 82.2%. Since 
the 1990 ACR criteria for PAN were derived from combined cohort of patients with PAN and MPA, we 
wished to explore how these criteria performed in a cohort of patients with PAN compared to patients 
with MPA. Results from these analyses highlight that the PAN criteria have poor sensitivity not only 
for MPA (28.9%), which is perhaps not surprising, but also for PAN (40.6%). The predominance of non-
HBV related PAN in our cohort (84.4%) could be one of the reasons for the low sensitivity of the criteria 
for this entity. However, poor performance of the 1990 ACR PAN criteria was previously reported with 
a sensitivity of 50.8%, when compared with other vasculitides as controls [15]. It is also interesting 
that specificity of the 1990 PAN classification criteria is similar for PAN and MPA (87.8 vs 88.5%). These 
comparative analyses highlight that the 1990 criteria for PAN are not fit for purpose to classify either 
patients with MPA and PAN. Furthermore, the lack of MPA recognition by 1990 ACR criteria may have 
affected not only performance of the PAN criteria, but also the criteria for the other small vessel 
vasculitides. 
The specificity of the ACR criteria for classification of most of the vasculitides within the DCVAS cohort 
was comparable with the original reports on the performance of the criteria. However, application of 
the criteria to the whole vasculitis cohort resulted in considerable overlap between types of AAV and 
PAN (Figure 2), which may have a negative impact on the criteria’s accuracy in classifying patients 
enrolled into clinical studies and trials [13]. It is important that the high specificity for classification is 
also derived from the analogous approach to the original ACR criteria development: Each criteria set 
was applied to all patients with PSV. With a total of 1095 patients in this study, among many had large-
vessel disease, the overall specificity for e.g. EPGA is likely to be high. Their unsuitability to distinguish 
between the more similar forms of PSV is demonstrated by their considerable overlap amongst these 
diagnoses (Figure 2). 
When the ACR criteria were applied to comparator patients (i.e. those without vasculitis), over a 
quarter of patients met at least one ACR criteria set, underscoring that the 1990 ACR classification 
criteria are not well suited for diagnostic use, as demonstrated previously [10]. The individual 
diagnostic specificity was however high for each individual criteria set. Since many of the patients 
included in the comparator groups did not have multisystem disease and hypereosinophilic disorders 
were rare, this may account for the particular high specificity e.g. for EGPA. 
This study has some limitations to consider. Firstly, DCVAS was collecting data only up to the time of 
diagnosis. Some potentially relevant data for the criteria like biopsy results could have been available 
only after the date of diagnosis. However, we formally asked investigators to report any change in 
diagnosis which might have occurred as a result of new information becoming available during the six 
months after the initial diagnosis. In contrast, for some patients in the original 1990 ACR cohort, 
autopsy data was included in the analysis [16]. The lower sensitivity found in the present analysis 
might thus be anticipated, however, over 70% of patients with AAV had a biopsy performed with the 
result available at the time of study enrolment. Furthermore, patients who were captured by the 
criteria did not differ in terms of available biopsy results from patients who were not. This makes a 
significant impact on sensitivity less likely, although in some cases diagnosis could be made based on 
clinical presentation and ANCA alone without biopsy results, hence highlighting the need for future 
incorporation of these tests. Secondly, the use of the clinical diagnosis submitted by the recruiting 
physician as the gold standard could lead to circularity in attempts to classify patients. 
Thirdly, centres may differ in their diagnostic approach, potentially leading to considerable 
heterogeneity in the criteria’s performance between centres. The validity of these findings, however, 
is augmented by the testing of the criteria in the largest and most heterogeneous cohort of patients 
with vasculitis recruited and the large number of specialised vasculitis centres worldwide participating 
in the study, the setting for which the 1990 ACR classification criteria were designed to be used. 
In conclusion, the results of this study emphasise the need for updated classification and diagnostic 
criteria for the systemic vasculitides that incorporate newer diagnostic modalities and potentially 
redefine the boundaries between the individual diseases.  
KEY MESSAGES: 
 At diagnosis, the sensitivity of the 1990 ACR Criteria for the vasculitides was low (67.1%). 
 There is a need for diagnostic criteria - as none exist, and the ACR criteria perform poorly if 
they are used as such. 
 There is a need for updated classification and diagnostic criteria for vasculitis that include 
MPA and incorporate some widely available tests.  
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 Figure 1: Study population. 
* Some comparator patients were used for more than one comparator group. 
§ The study was promoted at international conferences; all centres willing to participate were invited 
to take part in the study. At the time of this analysis data had been collected in rheumatology, renal, 
internal medicine, immunology and neurology centres in a total of 31 countries in Asia, Australasia, 
Europe, North America, and South America. 
DCVAS: Diagnostic & Classification in Vasculitis Study; PSV: primary systemic vasculitis; GPA: 
granulomatosis with polyangiitis; MPA: microscopic polyangiitis; ACR: American College of 
Rheumatology; GCA: giant cell arteritis; TAK: Takayasu’s arteritis; AAV: ANCA-associated vasculitis, 
IgAV: IgA-vasculitis.
 Figure 2. Accuracy and overlap of the application of the 1990 ACR classification criteria to patients 
with various forms of vasculitis 
(A) Patients in DCVAS with one of the forms of primary systemic vasculitis with existing 1990 ACR 
Criteria (n=944) that were: classified in accordance with physician’s submitted diagnosis (“Correctly 
Classified”), not classified in accordance with physician’s submitted diagnosis (“Misclassified”), or not 
classified by any of the ACR criteria sets (“Unclassified”); overlap between “Correctly Classified” and 
“Misclassified” includes patients who were classified by ACR criteria as having more than one 
diagnosis (one concordant and another non-concordant with physician’s submitted diagnosis.  
(B) The number of overlapping diagnoses when ACR 1990 criteria were applied to patients 
determined by the submitting physician as having a form of “small-vessel vasculitis”  
(C) The number of overlapping diagnoses when ACR 1990 criteria were applied to patients 
determined by the submitting physician as having a form of “large-vessel vasculitis”. 
DCVAS: Diagnostic & Classification Criteria in Vasculitis Study; ACR: American College of 
Rheumatology; GPA: granulomatosis with polyangiitis; PAN: polyarteritis nodosa; EGPA: eosinophilic 
granulomatosis with polyangiitis; TAK: Takayasu’s arteritis; GCA: giant cell arteritis.  
Unclassified
Misclassified
239
Correctly
classified
EGPA
GPA PAN
46
GCA TAK
633 179 236 98 281 50
A B C
107
4
1316
47 3
N=944 N=480 N=398
Table 1:  Sensitivity and specificity of the ACR 1990 classification criteria to classify and diagnose patients with and without 
vasculitis in DCVAS cohort 
  
  1990 ACR Criteria tested in the DCVAS population 1990 ACR Criteria performance 
characteristics in original cohort 
  Sensitivitya % (95% CI) Specificity % (95% CI) Sensitivity % Specificity % 
Vasculitis N  Classificationb Diagnosticc Classification 
GCA 345 81.1 (76.6 – 85.1) 94.9 (93.1 – 96.3) 64.2 (52.8 – 74.6) 93.5 91.2 
TAK 53 73.6 (59.7 – 84.7) 98.3 (97.3 – 99.0) 87.5 (67.6 – 97.3) 90.5 97.8 
GPA 275 65.6 (59.9 – 71.4) 88.7 (86.3 – 90.7) 88.0 (83.5 – 91.7) 88.2 92.0 
EGPA 79 57.0 (45.3 – 68.1) 99.8 (99.3 – 100) 98.9 (96.8 – 99.8) 85.0 99.7 
PAN 32 40.6 (23.7 – 59.4) 87.8 (85.7 – 89.7) 92.5 (88.7 – 95.7) 82.2 86.6 
MPA 94 28.9 (20.1 – 39.0) 88.5 (86.4 – 90.4) 92.5 (88.7 – 95.3) NS NS 
IGAV 66 72.7 (60.4 – 83.0) 96.3 (94.9 – 97.3) 90.4 (87.6 – 93.9) 87.1 87.7 
ACR: American College of Rheumatology; DCVAS: Diagnostic & Classification Criteria in Vasculitis Study; 95% CI: 95% 
confidence interval; GCA: giant cell arteritis; TAK: Takayasu’s arteritis; PAN: polyarteritis nodosa; MPA: microscopic 
polyangiitis; GPA: granulomatosis with polyangiitis; EGPA: eosinophilic granulomatosis with polyangiitis; IgAV: IgA-Vasculitis 
aSensitivity is the same for diagnosis and classification because the same vasculitis patients were used for both analyses. 
bIndividual ACR criteria were applied to all patients with PSV (N=1095) including 151 patients with other forms of vasculitis 
without existing ACR criteria (aortitis (n=7), other large vessel vasculitis (n=15), single organ vasculitis (n=25), undefined 
small vessel vasculitis (n=51), Behçet’s disease (n=30), other undefined primary vasculitis with no specific vessel size (n=2), 
cryoglobulinaemic vasculitis (n=12), and central nervous system vasculitis (n=9)). 
cIndividual ACR criteria were applied to vasculitis-specific comparators (GCA comparators: 81; AAV / PAN comparators: 267; 
IgAV comparators: 228; TAK comparators: 24); some of the comparators served for more than one form of vasculitis 
Table 2: Diagnostic workup by contributing centres 
Diagnostic tests No. of patients (%) Median by centre (IQR) 
GCA n=345 (45 centres) 3 (1-8) 
TA Biopsy, n (%) 289 (83.8) 100 (80-100) 
Ultrasound, n (%) 120 (34.8) 0 (0-68.8)a 
CTA/MRA, n (%) 50 (14.5) 0 (0-38) 
PET, n (%) 61 (17.8) 0 (0-10)b 
TAKAYASU’S ARTERITIS n=53 (23 centres) 2 (1-3) 
Biopsy, n (%) 12 (22.6) 0 (0-50) 
CTA/MRA/Ultrasound, n (%) 43 (81.1) 100 (71-100) 
PET, n (%) 13 (24.5) 0 (0-45) 
AAV/PAN n=546 (70 centres) 4 (2-10) 
ANCA, n (%) 545 (99.8) 100 (100-100) 
Biopsy, n (%) 416 (76.2) 88.2 (62.5-100) 
a Majority of ultrasound scans were performed by the major GCA-recruiting centres: 1 Slovenian, 
1 Swiss, 1 German (all with performance rate > 70%) and 4 UK centres (performance rate 9-33%). 
The centres that recruited less than 10 GCA patients infrequently performed ultrasound as a part 
of regular diagnostic workup. 
b PET-scans were performed in 12 centres in 9-100% of GCA patients/centre  
GCA: Giant Cell Arteritis; TA: Temporal artery; CTA: Computerized tomography angiogram; MRA: 
Magnetic resonance imaging – angiography; PET: Positron emission tomography; AAV: ANCA-
associated vasculitis; PAN: polyarteritis nodosa; ANCA: Antineutrophil cytoplasm antibodies 
  
Table 3:  Demographic data and non-criteria clinical characteristics of patients in DCVAS (n=944) who 
had primary systemic vasculitis of a type for which ACR criteria are available, sorted by 
whether patients were correctly or incorrectly classified by the 1990 ACR classification 
criteria 
Characteristic 
Correctly classified by  
the 1990 ACR criteria p-valuea 
  YES NOb   
ALL PATIENTS (n=944) 633 (67.1) 311 (32.9)  
Age, years (±SD) 60.9 (±17.6) 58.1 (±17.5) 0.022 
Sex (female) 360 (56.9) 178 (56.6) 0.944 
LARGE-VESSEL VASCULITIS (n=398) 319 (80.2) 79 (19.8)   
Age, years (±SD) 68.5 (±15.4) 63.3 (±15.7) 0.010 
LV-GCAc 5 (1.6) 26 (32.9) <0.001 
Vascular ultrasound performed 107 (33.5) 28 (35.4) 0.749 
Positive vascular ultrasound 84 (26.3) 22 (27.8) 0.785 
PET-scan performed 37 (11.6) 37 (46.8) <0.001 
Positive PET-scan  21 (6.6) 31 (39.2) <0.001 
MRA / CTA performed 63 (19.8) 26 (32.9) 0.012 
Positive MRA / CTA  49 (77.8) 23 (88.5) 0.005 
ANCA-ASSOCIATED VASCULITIS (n=448) 253 (56.5) 195 (43.5)   
Age, years (±SD) 54.3 (±15.2) 58.2 (±16.5) 0.009 
ANCA positive 221 (87.4) 171 (87.8) 0.914 
PR3 / MPO positive 218 (86.2) 161 (82.6) 0.295 
Limited diseased (only GPA and EGPA) 43 (19.0) 33 (25.8) 0.137 
Biopsy performed 193 (76.3) 139 (71.3) 0.231 
Consistent with vasculitise 136 (70.5) 99 (71.2) 0.881 
Figures refer to number of patients with characteristic and percentage of group, unless depicted otherwise. 
aDemographics and characteristics between patients with regards to classification by the ACR criteria were 
analysed using Pearson-χ²-test or t-test for equality of means, as appropriate. All p-values are two-tailed 
and were considered significant if < 0.05.  
bNot correctly classified by 1990 ACR criteria means that either they did not meet the criteria or were 
classified with a vasculitis not concordant with the one submitted by the investigator. 
cDefined as GCA with clinical or radiologic evidence of large-vessel involvement but without clinical 
evidence of cranial involvement. 
dDefined as GPA / EGPA with upper / lower respiratory tract disease without any other systemic 
involvement or constitutional symptoms. 
ebased on DCVAS items: “biopsy consistent with vasculitis but not definite” or “definite vasculitis” (not 
necessarily reflecting the ACR-biopsy definitions). 
DCVAS: Diagnostic & Classification Criteria in Vasculitis Study; ACR: American College of Rheumatology; 
ANCA: anti-neutrophil cytoplasm antibodies; PR3: proteinase 3, MPO: myeloperoxidase; CT: computed 
tomography; CTA: CT-angiography; MRA: MR-angiography; PET: Positron emission tomography; GCA: giant 
cell arteritis; TAK: Takayasu’s arteritis; PAN: polyarteritis nodosa; MPA: microscopic polyangiitis; GPA: 
granulomatosis with polyangiitis; EGPA: eosinophilic granulomatosis with polyangiitis; IgAV: IgA-Vasculitis. 
 
